Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended oral tranexamic acid after total hip or knee arthroplasty
ACTRN12625000926437Phase 4Not yet recruiting
- Sponsor
- North Sydney Orthopaedic Research Group
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tranexamic acid in osteoarthritis (OA) (2 arms), sponsored by North Sydney Orthopaedic Research Group. Primary endpoints: Patient-reported outcome measures specific to total hip arthroplasty and Patient-reported outcome measures specific to total knee arthroplasty. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12625000926437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000926437.